Juvmo (tavapadon)

Parkinson's disease

Also known as CVL-751

Manufacturer: AbbVie
Regulatory submission: NDA submitted September 2025
Launch: Expected by Citi analysts in the third quarter of 2026
Last updated: October 1, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

81 evidence topics · 31 sources

Levodopa12 evidence topics · 11 sources
Dopamine agonists12 evidence topics · 11 sources
Monoamine oxidase B inhibitors5 evidence topics · 5 sources
Catechol-O-methyltransferase inhibitors6 evidence topics · 4 sources
Amantadine4 evidence topics · 4 sources
Adenosine A2A receptor antagonists4 evidence topics · 4 sources
On-demand therapies5 evidence topics · 4 sources
Device-aided therapies14 evidence topics · 9 sources
Limitations of current therapies19 evidence topics · 19 sources